China’s germline growing pain

How Chinese regulatory authorities respond over the long term to the CRISPR baby furor could influence its industry’s success on the global stage, as domestic and international stakeholders seek reassurance that the authorities are on the case.

Arguably, this was a controversy waiting to happen. Until this past week, China had not taken a clear stance on human germline gene editing, even though Chinese labs had broken international norms in this field in the past...